Queens University Belfast – Confidence in Concept 2019
Lead Research Organisation:
Queen's University Belfast
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
People |
ORCID iD |
| Alan Stitt (Principal Investigator) |
Publications
Cornelius VA
(2021)
Diabetic endotheliopathy: RNA-binding proteins as new therapeutic targets.
in The international journal of biochemistry & cell biology
Cornelius VA
(2021)
Alternative Splicing: A Key Mediator of Diabetic Vasculopathy.
in Genes
Creane S
(2023)
In vitro evaluation of the potential use of snake-derived peptides in the treatment of respiratory infections using inhalation therapy: A proof of concept study
in European Journal of Pharmaceutical Sciences
McKelvey MC
(2022)
Cathepsin S Contributes to Lung Inflammation in Acute Respiratory Distress Syndrome.
in American journal of respiratory and critical care medicine
Quinn GP
(2022)
classifieR a flexible interactive cloud-application for functional annotation of cancer transcriptomes.
in BMC bioinformatics
Todd GM
(2020)
Secreted BMP antagonists and their role in cancer and bone metastases.
in Bone
Yang C
(2020)
Targeting QKI-7 in vivo restores endothelial cell function in diabetes.
in Nature communications
| Description | CLEC3B - a novel biomarker for heart failure: cohort evaluation and development of a point of care prototype |
| Amount | £85,525 (GBP) |
| Funding ID | NICHS - 2022_H01 - CLEC3B |
| Organisation | Northern Ireland Chest Heart and Stroke Association (NICHS) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 05/2024 |
| Description | Cathepsin S inhibition as a treatment for lung inflammation and lung damage in Chronic Lung Disease |
| Amount | £707,077 (GBP) |
| Funding ID | MR/X001504/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 01/2026 |
| Description | Development of vaccine to prevent Pseudomonas aeruginosa infection - North-South Research Programme 2021 |
| Amount | £3,000,000 (GBP) |
| Funding ID | HEA North South 2021 - Strand II - AVIRT via UCD |
| Organisation | Higher Education Authority |
| Sector | Public |
| Country | Ireland |
| Start | 02/2022 |
| End | 01/2026 |
| Description | Developmental Pathway Gap Fund (DPGF) |
| Amount | £226,068 (GBP) |
| Funding ID | MR/Y503447/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2024 |
| End | 09/2025 |
| Description | NXW 23 ICURe Discover: 'Development of Multi-Drug Sutures using Deep Eutectic Reactive Technology for the Prevention of Surgical Site Infections' |
| Amount | £3,500 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2023 |
| End | 06/2023 |
| Description | Opportunity Led Research: InflaTMP: Design of a novel combination anti-inflammatory and anti-viral biotherapeutic for COVID-19 targeting the NLRP3 inflammasome and TMPRSS2 |
| Amount | £143,000 (GBP) |
| Funding ID | HSC R&D COM/5627/20 |
| Organisation | Health and Social Care in Northern Ireland (HSCNI) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 03/2022 |
| Description | Opportunity-Led Professor Ultan Power - Repurposing FDA-approved drugs for treatment of 2019-nCoV-induced disease_x000D_ |
| Amount | £208,070 (GBP) |
| Funding ID | COM/5613/20 |
| Organisation | Public Health Agency (PHA) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2021 |
| Description | Repurposing approved drugs as potent antiviral combinations to treat COVID-19 disease. |
| Amount | £640,433 (GBP) |
| Funding ID | MRC - BMC DPFS - MR/W021641/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 12/2024 |
| Description | Research Development: NI COVID-19 Antibody Development Alliance |
| Amount | £265,500 (GBP) |
| Funding ID | INI - RD05201431 - NI Covid-19 Antibody Development Alliance |
| Organisation | Invest Northern Ireland |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2020 |
| End | 12/2021 |
| Description | Science Foundation Ireland (SFI) SDG Challenge: BIOTOPE 2 - Prize Phase |
| Amount | € 699,869 (EUR) |
| Organisation | Science Foundation Ireland (SFI) |
| Sector | Charity/Non Profit |
| Country | Ireland |
| Start | 11/2023 |
| End | 10/2025 |
| Description | Science Foundation Ireland (SFI) SDG Challenge: BIOTOPE 2 - Seed and Concept Phase |
| Amount | € 388,739 (EUR) |
| Organisation | Science Foundation Ireland (SFI) |
| Sector | Charity/Non Profit |
| Country | Ireland |
| Start | 06/2022 |
| End | 06/2024 |
| Description | Targeting Deubiquitinases to Treat Drug-Resistant Colorectal Cancer |
| Amount | £225,656 (GBP) |
| Funding ID | 56232 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2021 |
| End | 12/2023 |
| Title | ANTI VIRAL THERAPY |
| Description | The invention relates to novel compounds of formula (1), or pharmaceutically acceptable salts thereof, for use in treatment of viral infection. The invention further relates to methods of treating viral infection by administering a therapeutically effective amount of the compound of formula (1). |
| IP Reference | WO2022195296 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | Nothing as yet |
| Title | SUTURES |
| Description | The invention relates to a suture thread material comprising at least one polymer and at least one eutectic mixture. The polymer can be a biocompatible polymer such as polycaprolactone or PLGA. The eutectic mixture may comprise maleic acid and an antibiotic such as metronidazole. Other eutectic mixtures can be used in suture thread materials to reduce SSis and/or to decrease pain and/or to increase lubricity of sutures. The invention also provides a method for the production of sutures with drug loadings, the method comprising the use of therapeutic deep eutectic solvent (THEDES) technology to significantly increase drug content in suture matrices. |
| IP Reference | WO2022194900 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | Discussions around licensing |